Loading...
Cancer is associated with heightened risk for venous thromboembolism (VTE) but, paradoxically, also for bleeding complications. Unfortunately, determining whether initiating thromboprophylaxis for cancer patients would incur more benefit than harm is confounded by a lack of understanding about how risk for VTE in this population is influenced by tumor histology, treatment modalities, and patient characteristics.
To devise a simple model for identifying which cancer patients are at highest risk for VTE and, thus, most likely to benefit from thromboprophylaxis, investigators used a split-sample method to analyze more than 4000 consecutive participants in the Awareness of Neutropenia in Chemotherapy registry, an observational study of patients …